TP53-mutated (TP53-mt) myelodysplastic syndromes (MDS) are aggressive myeloid neoplasms associated with inferior responses to conventional chemotherapy and a high risk of progression to acute myeloid leukemia (AML).1-3 Although multiple targeted and immunotherapeutic strategies…
Donor age is an important factor influencing outcomes after allogeneic haematopoietic stem cell transplantation (allo-HSCT), but its relevance across donor types and distinct disease biology in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) remains unclear. We analysed 320 patients with AML/MDS who underwent first allo-HSCT between 2016 and 2024. Donors were categorized as matched or mismatched and further stratified as young (<35 years) or old (≥35 years).
CONFERENCE LOCATION:
Jack & Sheryl Morris Cancer Center
165 Somerset Street
New Brunswick, NJ 08901
PARKING:
There are two free parking options:
Valet Parking: Available at 15 Division Street, New Brunswick.
Self-Parking: Available in the Hardenberg Street Garage (18 Hardenberg Street, New Brunswick). Take the third-floor skybridge directly into the Cancer Center
I am a hematologist-oncologist who specializes in treating patients with acute myeloid leukemia (AML), myelodysplastic syndromes and bone marrow transplantation. Every day, I collaborate with my colleagues at the OSUCCC – James to create targeted therapies for each patient. Cancer is complex, but I’m confident our research continues to bring us closer to finding a cure. It’s an honor to work at one of the nation’s premier cancer hospitals. Our collective expertise results in faster responses, fewer side effects and more hope for cancer patients everywhere.
Highlight The 10-year incidence of non-cutaneous SM (6.8%) confirms its impact on late NRM. SM subtype distribution and timing vary by transplant: t-MDS/AML after auto-HCT, PTLD early after allo-HCT. PTLD declined markedly, nearly disappearing in the PTCy era with less ATG/Cord…
Abstract 6508 Background: Advances in hematopoietic stem cell transplantation (HSCT) have been driven by progress in supportive care, conditioning regimens, and graft-versus-host disease (GvHD) prophylaxis. Post-transplant morbidity and mortality are most pronounced in the first…
